Zenas BioPharma (ZBIO) Return on Sales (2023 - 2025)

Zenas BioPharma's Return on Sales history runs 3 years deep, the most recent figure standing at 0.39% for Q4 2025.

• On a quarterly basis, Return on Sales fell 28.0% year-over-year to 0.39% in Q4 2025; TTM through Dec 2025 was 0.39%, a 8.0% decrease from a year earlier, with the FY2025 full-year figure at 0.39%, down 7.0% from the prior year.
• Return on Sales retreated to 0.39% in Q4 2025 per ZBIO's latest filing, from 0.13% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q3 2023 and bottomed at 0.39% in Q4 2025.
• The 3-year median for Return on Sales is 0.1% (2024), against an average of 0.11%.
• Across the five-year window, Return on Sales decreased 3 bps in 2024 and decreased 28 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2023, then sank by 1565 bps to 0.1% in 2024, then slumped by 272 bps to 0.39% in 2025.
• Per Business Quant, the three latest ZBIO Return on Sales figures stand at 0.39% (Q4 2025), 0.13% (Q3 2025), and 0.12% (Q2 2025).